Drug intelligence / Profile preview

amphotericin B + caspofungin + voriconazole

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A triple antifungal combination therapy that combines three different classes of antifungal agents. This combination brings together amphotericin B (a polyene that forms pores in fungal cell membranes), caspofungin (an echinocandin that inhibits fungal cell wall synthesis), and voriconazole (a triazole that inhibits ergosterol biosynthesis). The triple combination has shown synergistic effects against Aspergillus species at specific concentrations, though interactions are concentration-dependent and can be antagonistic at higher concentrations of amphotericin B and voriconazole.

Targets

FKS (1,3-beta-D-glucan synthase component FKS1)CYP51A1 (Sterol 14α-demethylase)Ergosterol

Beyond the preview

Go deeper on amphotericin B + caspofungin + voriconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amphotericin B + caspofungin + voriconazole.

Explore the full profile